Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140768 | 0.84 | — | — | |
| SCHEMBL2614672 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TDP1SMN1; SMN2SLC25A5CA2 | |
| SCHEMBL5909830 | 0.78 | CES2 (0.44) | ALDH1A1TDP1SMN1; SMN2SLC25A5 | |
| SCHEMBL1226668 | 0.77 | SMN1; SMN2 (0.39) | ALDH1A1TDP1SMN1; SMN2SLC25A5CA2 | |
| SCHEMBL3602581 | 0.76 | POLB (0.39) | PIK3CDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27492997 | 0.75 | SMN1; SMN2 (0.38) | ALDH1A1TDP1SMN1; SMN2SLC25A5PDE4D | |
| SCHEMBL30724425 | 0.75 | PIK3CD (0.34) | PIK3CDSMN1; SMN2 | |
| SCHEMBL12449177 | 0.75 | PIK3CD (0.38) | PIK3CDALDH1A1SMN1; SMN2HCRTR2 | |
| SCHEMBL14883717 | 0.73 | CCNT1 (0.38) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL3596679 | 0.73 | PIK3CD (0.37) | PIK3CDALDH1A1TDP1HCRTR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-10 | — | — | US | disclosed |
| US-20220227786-A1 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-21 | — | — | US | disclosed |
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-11 | — | — | US | disclosed |
| EP-3512857-B1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | PIK3CD 3542/4885ALDH1A1 1647/4885TDP1 4441/4885 |
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | PIK3CD 3298/4885ALDH1A1 2638/4885TDP1 4083/4885 |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, MEN1 | PIK3CD 3298/4885ALDH1A1 2638/4885TDP1 4083/4885 |
| US-20220227786-A1 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | BMI1, MLLT1, MEN1 | PIK3CD 3298/4885ALDH1A1 2638/4885TDP1 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.